Jaguar Animal Health Inc
$ 1.10
7.84%
04 Dec - close price
- Market Cap 4,109,400 USD
- Current Price $ 1.10
- High / Low $ 1.10 / 1.00
- Stock P/E N/A
- Book Value 0.85
- EPS -2.58
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -4.12 %
- 52 Week High 33.25
- 52 Week Low 1.00
About
Jaguar Animal Health, Inc. (JAGX) is a commercial-stage biopharmaceutical company headquartered in San Francisco, focused on developing innovative prescription therapies for both human and animal health, with a primary emphasis on chronic gastrointestinal disorders and debilitating diarrhea. Utilizing proprietary technologies rooted in extensive research of the gastrointestinal microbiome, Jaguar Health is committed to delivering effective and sustainable healthcare solutions that enhance the quality of life for patients and their pets. As the demand for effective treatments in the gastrointestinal market continues to rise, Jaguar Health's advancements position it as a significant player in the biopharmaceutical landscape.
Analyst Target Price
$25.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-14 | 2025-05-12 | 2025-03-31 | 2024-11-12 | 2024-08-13 | 2024-05-14 | 2024-01-31 | 2023-11-14 | 2023-08-14 | 2023-05-15 | 2023-03-27 |
| Reported EPS | -6.28 | -10.26 | -18.7722 | -125.8 | -1.05 | -4.04 | -0.07 | -33 | -0.55 | -0.69 | -2.3881 | -3.4297 |
| Estimated EPS | -0.22 | -0.28 | -10.82 | -18.5 | -2.37 | -1.2 | -0.03 | -73.8 | -1.23 | -1.53 | -0.04 | -9.75 |
| Surprise | -6.06 | -9.98 | -7.9522 | -107.3 | 1.32 | -2.84 | -0.04 | 40.8 | 0.68 | 0.84 | -2.3481 | 6.3203 |
| Surprise Percentage | -2754.5455% | -3564.2857% | -73.4954% | -580% | 55.6962% | -236.6667% | -133.3333% | 55.2846% | 55.2846% | 54.902% | -5870.25% | 64.8236% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: JAGX
2025-10-24 00:00:00
Jaguar Health, Inc. announced the grant of restricted stock units (RSUs) to three new employees as an inducement to their employment, effective October 20, 2025. New Employee 1 and New Employee 2 each received 600 RSUs, while New Employee 3 received 300 RSUs, all vesting over one year from their hire date. These grants adhere to Nasdaq Listing Rule 5635(c)(4) and were approved by Jaguar's Compensation Committee.
2025-10-24 00:00:00
Jaguar Health, Inc. announced the grant of restricted stock units (RSUs) to three new employees on October 20, 2025, as part of an inducement material to their employment acceptance. The grants, consisting of 600 RSUs each for two employees and 300 RSUs for another, vest over one year, subject to continued service. These grants comply with Nasdaq Listing Rule 5635(c)(4).
2025-09-23 09:00:00
Jaguar Health (NASDAQ:JAGX) will be participating in two virtual investor conferences in September 2025. CEO Lisa Conte will present at the Emerging Growth Conference on September 25th and the Lytham Partners Fall 2025 Conference on September 30th, providing updates on near-term catalysts. Both presentations will be available online with replay options.
2025-08-19 20:15:00
Jaguar Health, Inc. announced that all seven proposals presented at its Annual Meeting of Stockholders on August 19, 2025, were approved. The company also highlighted upcoming presentations and initial proof-of-concept results for crofelemer in reducing parenteral nutrition for MVID and SBS-IF patients, alongside its strategy to seek business development partnerships for orphan indication products. Jaguar Health continues to advance its pharmaceutical development for gastrointestinal distress in both human and animal health.
2025-02-27 13:30:00
Jaguar Health, Inc. has adopted a limited-duration stockholder rights plan to protect long-term shareholder value following an indication of interest to acquire the company. The plan is designed to ensure the Board has sufficient time to evaluate potential acquisition offers and to encourage direct negotiation, while also providing several recognized stockholder protections. The company is actively pursuing multiple near-term catalysts, including clinical trials for crofelemer in rare diseases and cancer-related diarrhea, with key results and FDA meetings expected in Q2 2025.
2024-12-19 09:00:00
Jaguar Health's joint venture, Magdalena Biosciences, has successfully imported six kilograms of coca leaf from Peru for research into treating mental health indications such as ADHD or other neuropsychiatric conditions. This marks the second such import, authorized by the Peruvian Health Authority and acquired from Empresa Nacional de la Coca (ENACO). The imported coca leaf will be used to develop a Botanical Drug candidate, with Jaguar's Dr. Steven King set to present on its potential at the February 2025 Wisdom of the Leaf Coca Summit in Peru.
